Actuate Therapeutics Stock (NASDAQ:ACTU)

Ownership Financials Chart

Previous Close

$2.53

52W Range

$1.58 - $11.99

50D Avg

$2.84

200D Avg

$5.78

Market Cap

$70.42M

Avg Vol (3M)

$116.43K

Beta

0.86

Div Yield

ACTU Company Profile

Actuate Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapies for the treatment of cancers. The company's lead product candidate is Elraglusib Injection, a novel glycogen synthase kinase-3 inhibitor to treat metastatic pancreatic ductal adenocarcinoma. It also develops Elraglusib for the treatment of Ewing sarcoma, metastatic melanoma, and colorectal cancer. The company was formerly known as Apotheca Therapeutics, Inc. and changed its name to Actuate Therapeutics, Inc. in October 2015. The company was incorporated in 2015 and is based in Fort Worth, Texas.

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

Country

Employees

IPO Date

Aug 13, 2024

Website

ACTU Performance

ACTU Financial Summary

	Dec 25	Dec 24	Dec 23
Revenue	-	-	-
Operating Income	$-22.50M	$-25.16M	$-24.97M
Net Income	$-22.23M	$-27.29M	$-24.74M
EBITDA	$-22.50M	$-25.16M	$-24.43M
Basic EPS	$-1.06	$-3.26	$-1.65
Diluted EPS	$-1.06	$-3.26	$-1.65

Fiscal year ends in Dec 25 | Currency in USD

Peer Comparison

Ticker	Company
MOLN	Molecular Partners AG
ALEC	Alector, Inc.
SPRO	Spero Therapeutics, Inc.
NKTX	Nkarta, Inc.
VTGN	VistaGen Therapeutics, Inc.
MCRB	Seres Therapeutics, Inc.
VOR	Vor Biopharma Inc.
ELTX	Elicio Therapeutics, Inc.
PEPG	PepGen Inc.